The Various Effects of Gaseous Albuterol on Serum Lactate
| Status: | Completed |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | April 2015 |
| End Date: | August 2015 |
Empirical data from physician observation indicates an increase in serum lactate in acute
asthmatic patients being treated with inhaled albuterol therapy.
It is not clear if this increased serum lactate is in response to a physiological response
to the asthmatic process or from the albuterol treatment.
This study is designed to determine if administration of inhaled albuterol increases serum
lactate in healthy subjects.
asthmatic patients being treated with inhaled albuterol therapy.
It is not clear if this increased serum lactate is in response to a physiological response
to the asthmatic process or from the albuterol treatment.
This study is designed to determine if administration of inhaled albuterol increases serum
lactate in healthy subjects.
Approximately 30 healthy volunteers will be randomized to Albuterol or placebo. We powered
our study to detect a difference of 0.5 mmol/L, but hypothesize that the difference will be
greater than 1.0 mmol/L.
All volunteer subjects will sign a written consent, approved by the Institutional Review
Board. The intended pool of volunteers will be from residents, attendings, and medical
students in the hospital. The consent form will clearly specify that their participation in
the study will not impact their academic status or employment.
The subjects randomized to the Albuterol arm will receive a one hour 10 mg continuous
Albuterol nebulizer treatment. Those randomized to placebo will receive a one-hour saline
nebulizer treatment. The chief pharmacist for the study will randomly assign a number
between one and thirty to fifteen Albuterol treatments and fifteen placebo treatments.
Subjects will be monitored with cardiac monitor and serum lactate levels will be drawn every
15 minutes.
our study to detect a difference of 0.5 mmol/L, but hypothesize that the difference will be
greater than 1.0 mmol/L.
All volunteer subjects will sign a written consent, approved by the Institutional Review
Board. The intended pool of volunteers will be from residents, attendings, and medical
students in the hospital. The consent form will clearly specify that their participation in
the study will not impact their academic status or employment.
The subjects randomized to the Albuterol arm will receive a one hour 10 mg continuous
Albuterol nebulizer treatment. Those randomized to placebo will receive a one-hour saline
nebulizer treatment. The chief pharmacist for the study will randomly assign a number
between one and thirty to fifteen Albuterol treatments and fifteen placebo treatments.
Subjects will be monitored with cardiac monitor and serum lactate levels will be drawn every
15 minutes.
Inclusion Criteria:
- 18 years or older
Exclusion Criteria:
- Pregnant
- Prisoner
- beta agonist allergy
- hypokalemia
- taking furosemide, insulin, thiazide diuretics, metformin or acetazolamide
- coronary artery disease
- hyperthyroidism
- abnormal heart rhythm
- baseline serum lactate level >2.2 mmol/L
- baseline heart rate > 120
We found this trial at
1
site
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
